amgen glp-1 obesity drug market potential 2025 A Booming Weight-Loss Discovery Landscape at a Glance Obesity GLP-1 Market Size to
Description
Its the way we treat heart failure, HIV, tuberculosis, blood pressure, and many other diseases in medicine
2024;1(1) doi: 10.1038/s44355-024-00004-w
doi: 10.14218/JCTH.2024.00271, 23
Biochem Soc Symp
Insurance Exclusions and Prior Authorization Create Access Barriers Many insurance plans classify GLP-1 medications as non-essential weight loss drugs and exclude them entirely or require prior authorization tied to strict BMI thresholds
Up to 83% of participants on tirzepatide achieved an A1C of less than 7%
